Shingo Hatakeyama

137PUBLICATIONS
133CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersNeurology and neuromuscular diseasesPharmacogenomicsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (137)

|Oct 29, 2026
A Trial-Level Benefit-Toxicity Mapping Framework for Adjuvant Therapy in Renal Cell Carcinoma: A Focused Review.

|Oct 22, 2026
Development and Validation of the JIKEI-YAYOI Score for Predicting Castration Resistance in Metastatic Castration-Sensitive Prostate Cancer Treated With ARSI-Based Doublet Therapy.

|Sep 25, 2026
Association of time to upfront treatment initiation with outcomes in metastatic hormone-sensitive prostate cancer: a 4-month landmark analysis.

|Sep 21, 2026
Prognostic Stratification in High-Volume Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line Androgen Receptor Pathway Inhibitor-Based Combination Therapy.

|Sep 14, 2026
Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study.

|Aug 15, 2026
Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real-World Cohorts.

Pageof 23

Frequent Collaborators

21 joint publications

Naoki Fujita

13 joint publications

Teppei Okamoto

12 joint publications

Tohru Yoneyama

11 joint publications

Shintaro Narita